Recurrent hepatitis C and non-alcoholic fatty liver disease in transplanted patients: A review

Minerva Medica

Volumn 104, Issue 2, 2013, Pages 225-232

  Testino, G ^a   Sumberaz, A ^a   Leone, S ^a   Borro, P ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Hepatitis C; Liver transplantation; Metabolic syndrome; Non alcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; FATTY ACID; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE COURSE; DISEASE DURATION; FATTY LIVER; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ANTIVIRAL AGENTS; BODY MASS INDEX; CHOLESTEROL; FATTY LIVER; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER TRANSPLANTATION; RECURRENCE; TRIGLYCERIDES;

EID: 84877342685     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Bhat I, Mukherjee S. Hepatitis C recurrence after liver transplantation. Panminerva Med 2009;51:235-47.
2. Bihl F, Negro F. Treatment of chronic hepatitis C. Minerva Med 2009;100:459-65.
3. Testino G, Sumberaz A, Ancarani AO, Borro P, Ravetti G, Ansaldi F, Andorno E et al. Influence of body mass index, cholesterol, triglycerides and steatosis on Pegylated Interferon alfa-2a and Ribavirin treatment for recurrent hepatitis C in patients transplanted for HCV and alcoholic cirrhosis. Hepato-Gastroenterology 2009;56:501-3.
4. Ballardini G, De Raffele E, Groff P, Bioulac-Sage P, Grassi A, Ghetti S et al. Timing of reinfection and mechanisms of hepatocellular damage in transplanted HCV - infected liver. Liver Transpl 2002;8:10-20. (Pubitemid 34092667)
5. Gane E. Treatment of recurrent hepatitis C. Liver Transpl 2002;8(Suppl 1):S28-S37. (Pubitemid 35154040)
6. Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zeinn N. Recurrent hepatitis C after liver transplantation: on-treatment prefiction of response to Peginterferon/Ribavirin therapy. Liver Transpl 2008;14:53-8. (Pubitemid 351167989)
7. Testino G, Gentile R, Ansaldi F, Borro P, Ravetti G, Icardi G et al. Pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C: role of steatosis and body mass index. Panminerva Med 2009;51:135-6.
8. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 2010;55:56078.
9. Arrese M, Riquelme A, Soza A. Insulin resistance, hepatic steatosis and hepatitis C: a complex relationship with relevant clinical implications. Ann Hepatol 2010;9(Suppl):112-8.
10. Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut 2010;59:1279-87.
11. Kadayifci A. Metabolic syndrome and liver transplantation. Panminerva Med 2009;51:205-13.
12. Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 2008;14:1648-54.
13. Lizardi-Cervera J, Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol 2009;8(Suppl):S40-S3.
14. Gonzales-Reimers E, Castellano-Higuera A, Aleman-Valls R. Relation between body fat and liver fat accumulation and cytokine pattern in non-alcoholic patients with chronic HCV infection. Ann Nutr Metab 2009;55:351-7.
15. Testino G. Steatosis and hepatitis C. Recenti Prog Med 2005;96:621-3.
16. Farrell GC, George J, de la M. Hall P, McCullough AJ. Fatty liver disease. Oxford; Blackwell Publishing; 2005.
17. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weight connection. Hepatology 2010;51:1820-32.
18. Balsano C, Alisi A, Nobili V. Liver fibrosis and therapeutic strategies: the goal for improving metabolism. Current Drug Targets 2009;10:505-12.
19. Delgado JS. Evolving trends in non-alcoholic fatty liver disease. Eur J Intern Med 2008;19:75-82.
20. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43(2 Suppl 1):S99-S112.
21. Sattar PD. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. N Clin Sci (Lond) 2008;115:141-50.
22. Torres DM, Harrison SA. Current treatments in nonalcoholic steatohepatitis. Curr Treat Options Gastroenterol 2007;10:425-34. (Pubitemid 350284925)
23. Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham hearth study. Hepatology 2010;51:1979-87.
24. Fierbinteanu-Braticevici C, Mohora M, Tribus L, Petrisor A, Cretoiu SM, Cretoiu D. Hepatocyte steatosis in patients infected with genotype 1 hepatitis C virus. Rom J Morphol Embriol 2010;51:235-42.
25. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005;54:1003-8. (Pubitemid 40873917)
26. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Collordo G. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006;130:1636-42.
27. Delgado-Borrego A, Healey D, Negre B, Christofi M, Sabharwal S, Ludwig DA et al. Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr 2010;51:1-7.
28. Negro F. Hepatitis C virus-induced steatosis: an overview. Dig Dis 2010;28:294-9.
29. Hickman IJ, Powell EE, Prins JB, Clouston AD, Ash S, Purdie DM et at. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003;39:1042-8. (Pubitemid 37523778)
30. Clouston AD, Jonsson JR, Purdie DM, Macdonald GA, Pandeya N, Shorthouse C et al. Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol 2001;34:314-20. (Pubitemid 32176455)
31. Watanabe S, Yaginuma R, Ikejima K, Mnazaki A. Liver steatosis and metabolic syndrome. J Gastroenterol 2008;43:509-18.
32. Shifflet A, Wu GY. Non-alcoholic steatohepatitis: an overview. J Formos Med Ass 2009;108:4-12.
33. Alavian SM, Tabatabaei SV, Keshvari M, Behnava B, Miri SM, Elizee PK et al. Peginterferon alpha-2a and Ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Liver Int 2010;30:1173-80.
34. del Campo JA, Lopez RA, Romero-Gomez M. Insulin resistance and response to antiviral therapy in chronic hepatitis C: mechanisms and management. Dig Dis 2010;28:285-93.
35. Cross TJ, Quaglia A, Nolan J, Hughes S, Harrison PM. Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection? J Med Virol 2010;82:958-64.
36. Cross TJ, Rashid MM, Berry S, Harrison PM. The importance of steatosis in chronic hepatitis C infection and its management: a review. Hepatol Res 2010;40:237-47.
37. Testino G, Sumberaz A, Ravetti G, Gentile R, Ansaldi F, Icardi G. Pegylated interferon (PEG-IFN) alfa-2b and ribavirin for recurrent hepatitis C (genotype 1) after liver transplantation: relationship with steatosis. Digest Liver Dis 2006;38:864-5. (Pubitemid 44430935)
38. Testino G, Sumberaz A. Liver steatosis and antiviral therapy in chronic hepatitis C. Liver Int 2007;27:287. (Pubitemid 46680736)
39. Testino G, Ferro C, Sumberaz A, Messa P, Morelli N, Guadagni B et al. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular portosystemic stent shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepato-Gastroenterology 2003;50:1169-71.
40. Testino G, Ansaldi F, Andorno E, Ravetti GL, Ferro C, De Iaco F et al. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis. Hepato-Gastroenterology 2002;49:1636-8. (Pubitemid 35277343)
41. Ansaldi F, Bruzzone B, Testino G, Bassetti M, Gasparini R, Crovari P et al. Combination hepatitis C virus antigen and antibody immunoassay as a new tool for early diagnosis of infection. J Viral Hepatitis 2006;13:5-10.
42. Llado L, Castellote J, Figueras J. Is retrasplantation an option for recurrent hepatitis C cirrhosis after liver transplantation? J Hepatol 2005;42:468-72. (Pubitemid 40347307)
43. Perumalswami P, Kleiner DE, Lutchman G, Heller T, Borg B, Park Y et al. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology 2006;43:780-7.
44. Sumberaz A, Centenaro M, Ansaldi F, Ancarani AO, Andorno E, Icardi G et al. Relationship between laboratory parameters and intensive care unit stay post-liver transplantation: proposal of a model. Transplant Proc 2007;39:1868-70. (Pubitemid 47198839)
45. Wu C, Gilory R, Taylor R, Olyaee M, Abdulkarim B, Forster J et al. Alteration of hepatic nuclear receptor-mediated signaling pathways in HCV patients with and without a history of alcohol drinking. Hepatology 2011;54:1966-74.
46. Bonacini M. Alcohol use among patients with HIV infection. Annals of Hepatology 2011;10:502-7.
47. Curcio F, Di Martino F, Capraro C, Angelucci F, Bulla F, Caprio N et al. Together... to take care: multidisciplinary management of hepatitis C virus treatment in randomly selected drug users with chronic hepatitis. J Addict Med 2010;4:223-32.
48. Mas VR, Fassnacht R, Archer KJ, Maluf D. Molecular mechanisms involved in the interaction effects of alcohol and hepatitis C virus in liver cirrhosis. Mol Med 2010;16:287-97.
49. Testino G. Alcoholic diseases in hepato-gastroenteroogy: a point of view. Hepato-Gastroenterology 2008;55:371-7. (Pubitemid 351741464)
50. Pan Q, Metselaar HJ, de Ruiter P, Kwekkeboom J, Tilanus HW, Janssen HL et al. Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-alpha. Liver Transpl 2010;16:520-6.
51. ReVis-TC Study Group. Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study. Transplantation 2011;92:334-40.
52. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD et al. Non response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 in patients with chronic C, viral genotype 1. Gut 2006;55:529-35.
53. Bahr MJ, Manns MP. Recurrent hepatitis C in transplanted patients: more questions than answers. Dig Liver Dis 2003;35:2-6. (Pubitemid 36546654)
54. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010;139:1577-85.
55. Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010;51:1904-11.
56. Coto-Llerena M, Crespo G, González P, Koutsoudakis G, Miquel R, Navasa M et al. Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation. J Hepatol 2011;56:355-8.
57. Lange CM, Zeuzem S. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J Hepatol 2011;55:692-701.
58. Pascale A, Pais Raluca, Ratziu V. An overview of non-alcoholic steatohepatitis: past, present and future directions. J Gastrointestin Liver Dis 2010;19:415-23.
59. Testino G, Borro P. Hepatitis C recurrence: influence of serum cholesterol levels and liver steatosis on antiviral therapy. Hepatology 2011;53:1409-10.